(Q36164524)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15958710%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

review article

1 reference

title

Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15958710%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15958710%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

author name string

Stefan Balabanov

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15958710%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Lothar Kanz

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15958710%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Peter Brossart

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15958710%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Tim H Brümmendorf

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15958710%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

language of work or name

English

0 references

publication date

1 June 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15958710%20AND%20SRC:MED&resulttype=core&format=json

Annals of the New York Academy of Sciences

12 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15958710%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

volume

1044

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15958710%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

page(s)

168-177

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15958710%20AND%20SRC:MED&resulttype=core&format=json

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

12 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

ARG tyrosine kinase activity is inhibited by STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Asymmetric cell divisions sustain long-term hematopoiesis from single-sorted human fetal liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Imatinib alone and in combination for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Inhibitory effect of imatinib on normal progenitor cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Polycythemia vera responds to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Effects of imatinib on bone marrow engraftment in syngeneic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Dendritic cells in cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Origin, maturation and antigen presenting function of dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and t

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Dendritic cell survival and maturation are regulated by different signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Expression of relB is required for the development of thymic medulla and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and of IkappaB kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022

GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1349.022